Headquartered in Mountain View, CA Fiscal year ends September NYSE: ANRO altoneuroscience.com
Alto Neuroscience is a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, including treatment-resistant depression, major depressive disorder, bipolar depression, and schizophrenia. The company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify patients more likely to respond to its drug candidates. Its lead program, ALTO-207, is a fixed-dose combination of pramipexole and ondansetron designed to address treatment-resistant depression, currently in Phase 2b and planned Phase 3 trials. Additional pipeline candidates include ALTO-300 (MDD) and ALTO-100 (bipolar depression), both in Phase 2b trials. The company trades on the NYSE under the ticker ANRO and is pre-revenue, funding operations through equity capital raises. Updated
Are you looking for low-cost stocks to add to your portfolio? Doing so can be a challenge. After all, stocks that trade with low share prices are often risky investment opportunities. That’s…
Alto Neuroscience is a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, including treatment-resistant depression, major depressive disorder, bipolar depression, and schizophrenia.
The Wall Street consensus 12-month price target for ANRO is $38.38.
